menu search

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting
PCS12852 Shown to be Safe and Efficacious in Phase 2 Proof-of-Concept Trial in Gastroparesis Patients PCS12852 Improved Both Gastroparesis Symptom Scores and Gastric Emptying Rate HANOVER, MD, April 28, 2023 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic […] The post Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Dig... Read More
Posted: Apr 28 2023, 12:15
Author Name: forextv
Views: 111084

Search within

Pages Search Results: